[1]
I. Stević, “Antiobesity drugs utilization trend analysis and reimbursement lists status – the perspective of selected European countries”, arhfarm, vol. 74, no. Notebook 3, pp. 436–459, Jun. 2024, doi: 10.5937/arhfarm74-50851.